Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-69357 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ASAHL Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This target displays homology in the following species: Cow: 100%; Guinea Pig: 92%; Horse: 100%; Human: 100%; Mouse: 100%; Pig: 93%; Rabbit: 93%; Rat: 100%
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references NAAA-regulated lipid signaling governs the transition from acute to chronic pain.
Fotio Y, Jung KM, Palese F, Obenaus A, Tagne AM, Lin L, Rashid TI, Pacheco R, Jullienne A, Ramirez J, Mor M, Spadoni G, Jang C, Hohmann AG, Piomelli D
Science advances 2021 Oct 22;7(43):eabi8834
Science advances 2021 Oct 22;7(43):eabi8834
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of ASAHL on human 721_B cells. The sample was probed with a ASAHL polyclonal antibody (Product # PA5-69357) using a primary antibody dilution of 0.2-1.0 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of ASAHL in paraffin-embedded human liver tissue. Sample was probed with a ASAHL polyclonal antibody (Product # PA5-69357) at a dilution of 1:100. Detection was performed with a donkey anti-Rabbit Cy3 secondary antibody at a dilution of 1:200. Images were taken at 20x magnification with an exposure time of 0.5-2.0 seconds.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 7. A critical period for pain chronification. ( A ) Mice received formalin (1%) or saline and were assigned to seven groups ( n = 10 mice each): five received one dose of ARN19702 (30 mg kg -1 , IP) or Veh on PFD1 or PFD2 to PFD5; two additional groups received one daily dose of ARN19702 or Veh on PFD6-7 or PFD8-9. Contralateral hyperalgesia was assessed 2 weeks later. ( B ) Effects of ARN19702 (blue) or Veh (red) on CPLS establishment. Open circles, no formalin. ( C ) Time course of Naaa transcription in ipsilateral (left) or contralateral (right) L4-L6 hemicord of mice treated with Veh (open circles) or formalin (red circles). ( D to G ) Localization of immunoreactive NAAA (irNAAA) in ipsilateral L4-L6 hemicord of (D) Veh- and (E) formalin-injected mice (PFD4). NAAA partially colocalized with NeuN; other markers are shown in fig. S7. Magnification: x10 (D and E) or x40 [(E, bottom), zoom 2x]. Scale bar, 20 mum. DAPI, 4',6-diamidino-2-phenylindole. (F) Quantification of irNAAA in ipsilateral dorsal horn (DH), ventral horn (VH), and white matter (WM) in L5 cord of Veh- or formalin-injected mice. (G) Quantification of NAAA-immunoreactive NeuN + cells in ipsilateral DH and VH in L5 cord of Veh- or formalin-injected mice. ( H ) PEA levels in ipsilateral L4-L6 hemicord fragments of Veh- (open circles) or formalin-treated mice (red circles) (PFD4). ( I ) Effects of intrathecal ARN19702 or ARN077 (30 ng, 5 mul) at PFD2 and PFD4 on hypersensitivity at PFD14. ( J ) Effects of in